Overview

Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma

Status:
Terminated
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether bevacizumab can improve the outcome of treatment for patients with esophageal cancer whose disease is confined to the esophagus or the closely surrounding lymph nodes.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center
University of Michigan Rogel Cancer Center
Collaborator:
Genentech, Inc.
Treatments:
Albumin-Bound Paclitaxel
Bevacizumab
Cisplatin
Fluorouracil
Paclitaxel